Federal Register / Vol. 74, No. 202 / Wednesday, October 21, 2009 / Notices 54077 

to groundwater at the Site, including a 

Remedial Investigation/Feasibility 

Study and the selection of a remedy for 

contaminated groundwater at the Site. 

In exchange for the City’s payment, the 

City will receive from the United States 

a covenant not to sue or to take 

administrative action pursuant to 

Sections 106 or 107 of CERCLA, 42 

U.S.C. 9606 and 9607, as amended, for 

the performance of response actions at 

the Site and the United States’ past and 

future response costs at the Site. In 

addition, the City will dismiss its 

CERCLA claims against the Forest 

Service. The Department of Justice will 

receive for a period of thirty (30) days 

from the date of this publication 

comments relating to the Consent 

Decree. Comments should be addressed 

to the Acting Assistant Attorney 

General, Environment and Natural 

Resources Division, and either e-mailed 

to pubcomment-ees.enrd@usdoj.gov or 

mailed to P.O. Box 7611, U.S. 

Department of Justice, Washington, DC 

20044–7611, and should refer to United 

States of America v. El Dorado County, 

California, et al., Civil No. S–01–1520 

MCE GGH (E.D. Cal.) (DOJ Ref. No. 90– 

11–3–06554)(Consent Decree with City). 

The Consent Decree with the City may 

be examined at U.S. Department of 

Agriculture, Office of General Counsel, 

33 New Montgomery Street, 17th Floor, 

San Francisco, CA 94150 (contact Rose 

Miksovsky, (415) 744–3158). During the 

public comment period, the Consent 

Decree with the District may also be 

examined on the following Department 

of Justice Web site, http:// 

www.usdoj.gov/enrd/ 

Consent_Decrees.html. A copy of the 

Consent Decree with the City may also 

be obtained by mail from the Consent 

Decree Library, U.S. Department of 

Justice, P.O. Box 7611, Washington, DC 

20044–7611 or by faxing or e-mailing a 

request to Tonia Fleetwood 

(tonia.fleetwood@usdoj.gov), fax no. 

(202) 514–0097, phone confirmation 

number (202) 514–1547. In requesting a 

copy from the Consent Decree Library, 

please refer to United States of America 

v. El Dorado County, California, et al., 

Civil No. S–01–1520 MCE GGH (E.D. 

Cal.) (DOJ Ref. No. 90–11–3–06554) 

(Consent Decree with City), and enclose 

a check in the amount of $35.75 (25 

cents per page reproduction cost) 

payable to the U.S. Treasury or, if by 

e-mail or fax, forward a check in that 

amount to the Consent Decree Library at 

the stated address. 

Maureen Katz, 

Assistant Section Chief, Environmental 

Enforcement Section, Environment and 

Natural Resources Division. 

[FR Doc. E9–25216 Filed 10–20–09; 8:45 am] 

BILLING CODE 4410–15–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–317F] 

Controlled Substances: Final Revised 

Aggregate Production Quotas for 2009 

AGENCY: Drug Enforcement 

Administration (DEA), Justice. 

ACTION: Notice of final aggregate 

production quotas for 2009. 

SUMMARY: This notice establishes final 

2009 aggregate production quotas for 

controlled substances in schedules I and 

II of the Controlled Substances Act 

(CSA). The DEA has taken into 

consideration comments received in 

response to a notice of the proposed 

revised aggregate production quotas for 

2009 published July 23, 2009 (74 FR 

36511). 

DATES: Effective Date: October 21, 2009. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, Ph.D, Chief, 

Drug and Chemical Evaluation Section, 

Drug Enforcement Administration, 8701 

Morrissette Drive, Springfield, Virginia 

22152, Telephone: (202) 307–7183. 

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in schedules I and II. This responsibility 

has been delegated to the Administrator 

of the DEA by 28 CFR 0.100. The 

Administrator, in turn, has redelegated 

this function to the Deputy 

Administrator, pursuant 28 CFR 0.104. 

The 2009 aggregate production quotas 

represent those quantities of controlled 

substances in schedules I and II that 

may be produced in the United States in 

2009 to provide adequate supplies of 

each substance for: The estimated 

medical, scientific, research, and 

industrial needs of the United States; 

lawful export requirements; and the 

establishment and maintenance of 

reserve stocks (21 U.S.C. 826(a) and 21 

CFR 1303.11). These quotas do not 

include imports of controlled 

substances. 

On July 23, 2009, a notice of the 

proposed revised 2009 aggregate 

production quotas for certain controlled 

substances in schedules I and II was 

published in the Federal Register (74 

FR 36511). All interested persons were 

invited to comment on or object to these 

proposed aggregate production quotas 

on or before August 24, 2009. 

Seven companies commented on a 

total of 18 schedules I and II controlled 

substances within the published 

comment period. Seven companies 

proposed that the aggregate production 

quotas for amphetamine (for sale), 

codeine (for conversion), 

dihydromorphine, fentanyl, 

hydrocodone (for sale), hydromorphone, 

lisdexamfetamine, methadone, 

methadone intermediate, 

methamphetamine (for sale), 

methylphenidate, nabilone, opium 

(tincture), oxycodone (for sale), 

oxycodone (for conversion), 

oxymorphone (for sale), phenylacetone, 

and thebaine were insufficient to 

provide for the estimated medical, 

scientific, research, and industrial needs 

of the United States, for export 

requirements and for the establishment 

and maintenance of reserve stocks. 

DEA has taken into consideration the 

above comments along with the relevant 

2008 year-end inventories, initial 2009 

manufacturing quotas, 2009 export 

requirements, actual and projected 2009 

sales, research, product development 

requirements, and additional 

applications received. Based on this 

information, the DEA has adjusted the 

final 2009 aggregate production quotas 

for amphetamine (for conversion), 

dihydromorphine, hydrocodone (for 

sale), hydromorphone, 

lisdexamfetamine, morphine (for sale), 

opium (tincture), oxycodone (for sale), 

oxycodone (for conversion), 

oxymorphone (for sale), and 

phenylacetone to meet the legitimate 

needs of the United States. 

Regarding amphetamine (for sale), 

codeine (for conversion), fentanyl, 

methadone, methadone intermediate, 

methamphetamine (for sale), 

methylphenidate, nabilone, and 

thebaine, the DEA has determined that 

the proposed revised 2009 aggregate 

production quotas are sufficient to meet 

the current 2009 estimated medical, 

scientific, research, and industrial needs 

of the United States and to provide for 

adequate inventories. 

Therefore, under the authority vested 

in the Attorney General by Section 306 

of the CSA (21 U.S.C. § 826), and 

delegated to the Administrator of the 

DEA by 28 CFR 0.100, and redelegated 

to the Deputy Administrator, pursuant 

to 28 CFR 0.104, the Deputy 

Administrator hereby orders that the 

2009 final aggregate production quotas 

for the following controlled substances, 


jlentini on DSKJ8SOYB1PROD with NOTICES
54078 Federal Register / Vol. 74, No. 202 / Wednesday, October 21, 2009 / Notices 

expressed in grams of anhydrous acid or 

base, be established as follows: 

Basic class—Schedule I Final revised 

2009 quotas 

2,5–Dimethoxyamphetamine ..................................................................................................................................... 2 g 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ............................................................................................................ 2 g 

3-Methylfentanyl ......................................................................................................................................................... 2 g 

3-Methylthiofentanyl ................................................................................................................................................... 2 g 

3,4-Methylenedioxyamphetamine (MDA) .................................................................................................................. 25 g 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ................................................................................................... 10 g 

3,4-Methylenedioxymethamphetamine (MDMA) ....................................................................................................... 20 g 

3,4,5-Trimethoxyamphetamine .................................................................................................................................. 2 g 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ............................................................................................................ 2 g 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ........................................................................................................ 2 g 

4-Methoxyamphetamine ............................................................................................................................................ 27 g 

4-Methylaminorex ...................................................................................................................................................... 2 g 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ............................................................................................................ 2 g 

5-Methoxy-3,4-methylenedioxyamphetamine ............................................................................................................ 2 g 

5-Methoxy-N,N-diisopropyltryptamine ........................................................................................................................ 5 g 

Acetyl-alpha-methylfentanyl ....................................................................................................................................... 2 g 

Acetyldihydrocodeine ................................................................................................................................................. 2 g 

Acetylmethadol .......................................................................................................................................................... 2 g 

Allylprodine ................................................................................................................................................................ 2 g 

Alphacetylmethadol .................................................................................................................................................... 2 g 

Alpha-ethyltryptamine ................................................................................................................................................ 2 g 

Alphameprodine ......................................................................................................................................................... 2 g 

Alphamethadol ........................................................................................................................................................... 2 g 

Alpha-methylfentanyl ................................................................................................................................................. 2 g 

Alpha-methylthiofentanyl ............................................................................................................................................ 2 g 

Aminorex .................................................................................................................................................................... 2 g 

Benzylmorphine ......................................................................................................................................................... 2 g 

Betacetylmethadol ..................................................................................................................................................... 2 g 

Beta-hydroxy-3-methylfentanyl .................................................................................................................................. 2 g 

Beta-hydroxyfentanyl ................................................................................................................................................. 2 g 

Betameprodine ........................................................................................................................................................... 2 g 

Betamethadol ............................................................................................................................................................. 2 g 

Betaprodine ................................................................................................................................................................ 2 g 

Bufotenine .................................................................................................................................................................. 3 g 

Cathinone ................................................................................................................................................................... 3 g 

Codeine-N-oxide ........................................................................................................................................................ 602 g 

Diethyltryptamine ....................................................................................................................................................... 2 g 

Difenoxin .................................................................................................................................................................... 3,000 g 

Dihydromorphine ........................................................................................................................................................ 3,132,000 g 

Dimethyltryptamine .................................................................................................................................................... 3 g 

Gamma-hydroxybutyric acid ...................................................................................................................................... 24,200,00 g 

Heroin ........................................................................................................................................................................ 20 g 

Hydromorphinol .......................................................................................................................................................... 2 g 

Hydroxypethidine ....................................................................................................................................................... 2 g 

Ibogaine ..................................................................................................................................................................... 1 g 

Lysergic acid diethylamide (LSD) .............................................................................................................................. 10 g 

Marihuana .................................................................................................................................................................. 4,500,000 g 

Mescaline ................................................................................................................................................................... 7 g 

Methaqualone ............................................................................................................................................................ 5 g 

Methcathinone ........................................................................................................................................................... 4 g 

Methyldihydromorphine .............................................................................................................................................. 2 g 

Morphine-N-oxide ...................................................................................................................................................... 605 g 

N-Benzylpiperazine .................................................................................................................................................... 2 g 

N,N-Dimethylamphetamine ........................................................................................................................................ 7 g 

N-Ethylamphetamine ................................................................................................................................................. 2 g 

N-Hydroxy-3,4-methylenedioxyamphetamine ............................................................................................................ 2 g 

Noracymethadol ......................................................................................................................................................... 2 g 

Norlevorphanol ........................................................................................................................................................... 52 g 

Normethadone ........................................................................................................................................................... 2 g 

Normorphine .............................................................................................................................................................. 16 g 

Para-fluorofentanyl ..................................................................................................................................................... 2 g 

Phenomorphan .......................................................................................................................................................... 2 g 

Pholcodine ................................................................................................................................................................. 2 g 

Psilocybin ................................................................................................................................................................... 7 g 

Psilocyn ...................................................................................................................................................................... 7 g 

Tetrahydrocannabinols .............................................................................................................................................. 312,500 g 

Thiofentanyl ............................................................................................................................................................... 2 g 

Trimeperidine ............................................................................................................................................................. 2 g 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 202 / Wednesday, October 21, 2009 / Notices 54079 

Basic class—Schedule II Final revised 

2009 quotas 

1-Phenylcyclohexylamine .......................................................................................................................................... 2 g 

1-Piperdinocyclohexanecarbonitrile ........................................................................................................................... 2 g 

Alfentanil .................................................................................................................................................................... 8,000 g 

Alphaprodine .............................................................................................................................................................. 2 g 

Amobarbital ................................................................................................................................................................ 3 g 

Amphetamine (for sale) ............................................................................................................................................. 17,000,000 g 

Amphetamine (for conversion) .................................................................................................................................. 7,500,000 g 

Cocaine ...................................................................................................................................................................... 247,000 g 

Codeine (for sale) ...................................................................................................................................................... 39,605,000 g 

Codeine (for conversion) ........................................................................................................................................... 65,000,000 g 

Dextropropoxyphene .................................................................................................................................................. 106,000,000 g 

Dihydrocodeine .......................................................................................................................................................... 1,200,000 g 

Diphenoxylate ............................................................................................................................................................ 947,000 g 

Ecgonine .................................................................................................................................................................... 83,000 g 

Ethylmorphine ............................................................................................................................................................ 2 g 

Fentanyl ..................................................................................................................................................................... 1,428,000 g 

Glutethimide ............................................................................................................................................................... 2 g 

Hydrocodone (for sale) .............................................................................................................................................. 55,500,000 g 

Hydromorphone ......................................................................................................................................................... 3,340,000 g 

Isomethadone ............................................................................................................................................................ 2 g 

Levo-alphacetylmethadol (LAAM) .............................................................................................................................. 3 g 

Levomethorphan ........................................................................................................................................................ 5 g 

Levorphanol ............................................................................................................................................................... 10,000 g 

Lisdexamfetamine ...................................................................................................................................................... 8,200,000 g 

Meperidine ................................................................................................................................................................. 8,600,000 g 

Meperidine Intermediate-A ........................................................................................................................................ 3 g 

Meperidine Intermediate-B ........................................................................................................................................ 7 g 

Meperidine Intermediate-C ........................................................................................................................................ 3 g 

Metazocine ................................................................................................................................................................. 1 g 

Methadone (for sale) ................................................................................................................................................. 25,000,000 g 

Methadone Intermediate ............................................................................................................................................ 26,000,000 g 

Methamphetamine ..................................................................................................................................................... 3,130,000 g 

Methylphenidate ......................................................................................................................................................... 50,000,000 g 

Morphine (for sale) .................................................................................................................................................... 36,300,000 g 

Morphine (for conversion) .......................................................................................................................................... 100,000,000 g 

Nabilone ..................................................................................................................................................................... 9,002 g 

Noroxymorphone (for sale) ........................................................................................................................................ 10,000 g 

Noroxymorphone (for conversion) ............................................................................................................................. 9,000,000 g 

Opium (powder) ......................................................................................................................................................... 230,000 g 

Opium (tincture) ......................................................................................................................................................... 1,250,000 g 

Oripavine .................................................................................................................................................................... 15,000,000 g 

Oxycodone (for sale) ................................................................................................................................................. 94,000,000 g 

Oxycodone (for conversion) ...................................................................................................................................... 4,500,000 g 

Oxymorphone (for sale) ............................................................................................................................................. 2,570,000 g 

Oxymorphone (for conversion) .................................................................................................................................. 12,000,000 g 

Pentobarbital .............................................................................................................................................................. 28,000,000 g 

Phenazocine .............................................................................................................................................................. 1 g 

Phencyclidine ............................................................................................................................................................. 20 g 

Phenmetrazine ........................................................................................................................................................... 2 g 

Phenylacetone ........................................................................................................................................................... 250,001 g 

Racemethorphan ....................................................................................................................................................... 2 g 

Remifentanil ............................................................................................................................................................... 500 g 

Secobarbital ............................................................................................................................................................... 67,000 g 

Sufentanil ................................................................................................................................................................... 10,300 g 

Thebaine .................................................................................................................................................................... 126,000,000 g 

DEA proposed the aggregate 

production quota for tapentadol at 

519,000 g in the 2009 proposed revised 

aggregate production quota notice 

published on July 23, 2009, in the 

Federal Register (74 FR 36511). 

Tapentadol is no longer listed because 

the material will be imported into the 

United States and not manufactured 

domestically. 

The Deputy Administrator further 

orders that the aggregate production 

quotas for all other schedules I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 shall be zero. 

The Office of Management and Budget 

has determined that notices of aggregate 

production quotas are not subject to 

centralized review under Executive 

Order 12866. 

This action does not preempt or 

modify any provision of state law; nor 

does it impose enforcement 

responsibilities on any state; nor does it 

diminish the power of any state to 

enforce its own laws. Accordingly, this 

action does not have federalism 

implications warranting the application 

of Executive Order 13132. 

The Deputy Administrator hereby 

certifies that this action will have no 

significant impact upon small entities, 

whose interests must be considered 

under the Regulatory Flexibility Act, 5 

U.S.C. 601 et seq. The establishment of 

aggregate production quotas for 

schedules I and II controlled substances 

is mandated by law and by international 

treaty obligations. The quotas are 


jlentini on DSKJ8SOYB1PROD with NOTICES
54080 Federal Register / Vol. 74, No. 202 / Wednesday, October 21, 2009 / Notices 

necessary to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, for 

export requirements and the 

establishment and maintenance of 

reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by state, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $120,000,000 or more 

in any one year, and will not 

significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

This action is not a major rule as 

defined by Section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996. This action will 

not result in an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 

Dated: October 13, 2009. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. E9–25274 Filed 10–20–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[DEA # 318E] 

Controlled Substances: Established 

Initial Aggregate Production Quotas 

for 2010 

AGENCY: Drug Enforcement 

Administration (DEA), Justice. 

ACTION: Notice of aggregate production 

quotas for 2010. 

SUMMARY: This notice establishes initial 

2010 aggregate production quotas for 

controlled substances in schedules I and 

II of the Controlled Substances Act 

(CSA). 

DATES: Effective Date: October 21, 2009. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, Ph.D, Chief, 

Drug & Chemical Evaluation Section, 

Drug Enforcement Administration, 

Washington, DC 20537, Telephone: 

(202) 307–7183. 

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in schedules I and II. This responsibility 

has been delegated to the Administrator 

of the DEA by 28 CFR 0.100. The 

Administrator, in turn, has redelegated 

this function to the Deputy 

Administrator, pursuant to 28 CFR 

0.104. 

The 2010 aggregate production quotas 

represent those quantities of controlled 

substances that may be produced in the 

United States in 2010 to provide 

adequate supplies of each substance for: 

the estimated medical, scientific, 

research and industrial needs of the 

United States; lawful export 

requirements; and the establishment 

and maintenance of reserve stocks (21 

U.S.C. 826(a) and 21 CFR 1303.11). 

These quotas do not include imports of 

controlled substances for use in 

industrial processes. 

On May 21, 2009, a notice of the 

proposed initial 2010 aggregate 

production quotas for certain controlled 

substances in schedules I and II was 

published in the Federal Register (74 

FR 23881). All interested persons were 

invited to comment on or object to these 

proposed aggregate production quotas 

on or before June 22, 2009. 

Twelve responses (eleven from DEA 

registered manufacturers, and one from 

a non-DEA registrant) were received 

within the published comment period, 

offering comments on a total of 28 

schedule I and II controlled substances. 

One additional comment was received 

after the comment period ended and 

therefore was not considered. The 

commenters stated that the proposed 

aggregate production quotas for 3,4- 

methylenedioxyamphetamine, 3,4- 

methylenedioxyethylamphetamine, 3,4- 

methylenedioxymethamphetamine, 

alfentanil, amphetamine (for sale), 

codeine (for sale), codeine (for 

conversion), dihydromorphine, 

fentanyl, gamma hydroxybutyric acid, 

hydrocodone, hydromorphone, 

isomethadone, levo-desoxyephedrine, 

levorphanol, lisdexamfetamine, 

methamphetamine (for sale), morphine 

(for conversion), nabilone, opium 

(tincture), oxycodone (for sale), 

oxycodone (for conversion), 

oxymorphone (for sale), remifentanil, 

sufentanil, tapentadol, 

tetrahydrocannabinols, and thebaine 

were insufficient to provide for the 

estimated medical, scientific, research 

and industrial needs of the United 

States, for export requirements and for 

the establishment and maintenance of 

reserve stocks. 

In arriving at the aggregate production 

quotas, DEA has taken into 

consideration the above comments 

along with the factors set forth at 21 

CFR 1303.11(b) and other relevant 2009 

factors, including 2009 manufacturing 

quotas, current 2009 sales and 

inventories, 2010 export requirements, 

additional applications received, and 

research and product development 

requirements. Based on this 

information, DEA has adjusted the 

initial aggregate production quotas for 4- 

methoxyamphetamine, alphamethyltryptamine, amphetamine (for 

conversion), dihydromorphine, 

isomethadone, levo-desoxyephedrine, 

lisdexamfetamine, lysergic acid 

diethylamide, methamphetamine (for 

sale), methamphetamine (for 

conversion), methaqualone, oxycodone 

(for sale), oxycodone (for conversion), 

oxymorphone (for sale) and 

phenylacetone to meet the legitimate 

needs of the United States. 

DEA proposed the aggregate 

production quota for tapentadol at 

519,000 g in the 2010 proposed initial 

aggregate production quota notice 

published on May 21, 2009 in the 

Federal Register (74 FR 23881). 

Tapentadol is no longer listed because 

the material will be imported into the 

United States and not manufactured 

domestically. 

Regarding 3,4- 

methylenedioxyamphetamine, 3,4- 

methylenedioxyethylamphetamine, 3,4- 

methylenedioxymethamphetamine, 

alfentanil, amphetamine (for sale), 

codeine (for sale), codeine (for 

conversion), fentanyl, gamma 

hydroxybutyric acid, hydrocodone, 

hydromorphone, levorphanol, morphine 

(for conversion), nabilone, opium 

(tincture), remifentanil, sufentanil, 

tetrahydrocannabinols, and thebaine 

DEA has determined that the proposed 

initial 2010 aggregate production quotas 

are sufficient to meet the current 2010 

estimated medical, scientific, research 

and industrial needs of the United 

States. 

Pursuant to 21 CFR 1303, the Deputy 

Administrator of DEA will, in 2010, 

adjust aggregate production quotas and 

individual manufacturing quotas 

allocated for the year based upon 2009 

year-end inventory and actual 2009 

disposition data supplied by quota 

recipients for each basic class of 

schedule I or II controlled substance. 


jlentini on DSKJ8SOYB1PROD with NOTICES